Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | CA4 | P22748 | 2/20 | 0.45 |
| ▸ | CA6 | P23280 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.45 |
| ▸ | CCNB2 | O95067 | 3/20 | 0.45 |
| ▸ | CDK1 | P06493 | 3/20 | 0.45 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.45 |
| ▸ | GSK3B | P49841 | 3/20 | 0.45 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.45 |
| ▸ | CDK5R1 | Q15078 | 3/20 | 0.45 |
| ▸ | CCNB3 | Q8WWL7 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.44 |
| ▸ | HTR2C | P28335 | 5/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | HTR2A | P28223 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1987936 | 0.91 | MEN1 (0.50) | CA1CA2CA4CA6MEN1 | |
| SCHEMBL1987063 | 0.91 | MEN1 (0.45) | CA1CA2CA4CA6MEN1 | |
| SCHEMBL1986107 | 0.87 | MEN1 (0.54) | CA1CA2CA4CA6MEN1 | |
| SCHEMBL1987355 | 0.86 | CCNB2 (0.59) | CA1CA2CA4CA6MEN1 | |
| SCHEMBL1984257 | 0.86 | GSK3B (0.53) | CA1CA2CA4CA6MEN1 | |
| SCHEMBL1985758 | 0.84 | KMT2A (0.66) | CA1CA2CA4CA6MEN1 | |
| SCHEMBL12602922 | 0.80 | KDM4E (0.48) | CA1CA2CA4CA6MEN1 | |
| SCHEMBL12602356 | 0.79 | MEN1 (0.42) | CA1CA2CA4CA6MEN1 | |
| SCHEMBL15497465 | 0.79 | TDP1 (0.45) | CA1CA2CA4CA6MEN1 | |
| SCHEMBL1985543 | 0.79 | GSK3B (0.53) | CA1CA2CA4CA6MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9303037-B2 | Tetracyclic heteroatom containing derivatives useful as sex steroid hormone receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2016-04-05 | — | — | US | disclosed |
| US-9303037-B2 | Tetracyclic heteroatom containing derivatives useful as sex steroid hormone receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2016-04-05 | — | — | US | disclosed |
| US-20140066479-A1 | NOVEL TETRACYCLIC HETEROATOM CONTAINING DERIVATIVES USEFUL AS SEX STEROID HORMONE RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-03-06 | — | — | US | disclosed |
| US-20140066479-A1 | NOVEL TETRACYCLIC HETEROATOM CONTAINING DERIVATIVES USEFUL AS SEX STEROID HORMONE RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-03-06 | — | — | US | disclosed |
| EP-1796664-B1 | NOVEL TETRACYCLIC HETEROATOM CONTAINING DERIVATIVES USEFUL AS SEX STEROID HORMONE RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2013-11-27 | — | — | EP | disclosed |
| US-8580840-B2 | Tetracyclic heteroatom containing derivatives useful as sex steroid hormone receptor modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2013-11-12 | — | — | US | disclosed |
| US-8580840-B2 | Tetracyclic heteroatom containing derivatives useful as sex steroid hormone receptor modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2013-11-12 | — | — | US | disclosed |
| US-8580840-B2 | Tetracyclic heteroatom containing derivatives useful as sex steroid hormone receptor modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2013-11-12 | — | — | US | disclosed |
| US-8318766-B2 | Tetracyclic heteroatom containing derivatives useful as sex steroid hormone receptor modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-11-27 | — | — | US | disclosed |
| US-8318766-B2 | Tetracyclic heteroatom containing derivatives useful as sex steroid hormone receptor modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-11-27 | — | — | US | disclosed |
| US-20080114048-A1 | NOVEL TETRACYCLIC HETEROATOM CONTAINING DERIVATIVES USEFUL AS SEX STEROID HORMONE RECEPTOR MODULATORS | SUI ZHIHUA | 2008-05-15 | — | — | US | disclosed |
| EP-1907394-A1 | NOVEL TETRACYCLIC HETEROATOM CONTAINING DERIVATIVES USEFUL AS SEX STEROID HORMONE RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-04-09 | — | — | EP | disclosed |
| US-7338973-B2 | Tetracyclic heteroatom containing derivatives useful as sex steroid hormone receptor modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-03-04 | — | — | US | disclosed |
| US-7338973-B2 | Tetracyclic heteroatom containing derivatives useful as sex steroid hormone receptor modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-03-04 | — | — | US | disclosed |
| US-7338973-B2 | Tetracyclic heteroatom containing derivatives useful as sex steroid hormone receptor modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-03-04 | — | — | US | disclosed |
| EP-1796664-A1 | NOVEL TETRACYCLIC HETEROATOM CONTAINING DERIVATIVES USEFUL AS SEX STEROID HORMONE RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-06-20 | — | — | EP | disclosed |
| US-20060116513-A1 | Novel tetracyclic heteroatom containing derivatives useful as sex steroid hormone receptor modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-01 | — | — | US | disclosed |
| US-20060116415-A1 | Novel tetracyclic heteroatom containing derivatives useful as sex steroid hormone receptor modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-01 | — | — | US | disclosed |
| WO-2006047017-A1 | NOVEL TETRACYCLIC HETEROATOM CONTAINING DERIVATIVES USEFUL AS SEX STEROID HORMONE RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-05-04 | — | — | WO | disclosed |
| WO-2006034090-A1 | NOVEL TETRACYCLIC HETEROATOM CONTAINING DERIVATIVES USEFUL AS SEX STEROID HORMONE RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116415-A1 | Novel tetracyclic heteroatom containing derivatives useful as sex steroid hormone receptor modulators | NR5A1, ESRRA, SHBG | CA1 3310/4885CA2 2714/4885CA4 3869/4885 |
| US-20060116513-A1 | Novel tetracyclic heteroatom containing derivatives useful as sex steroid hormone receptor modulators | NR5A1, ESRRA, SHBG | CA1 3310/4885CA2 2714/4885CA4 3869/4885 |
| US-20140066479-A1 | NOVEL TETRACYCLIC HETEROATOM CONTAINING DERIVATIVES USEFUL AS SEX STEROID HORMONE RECEPTOR MODULATORS | NR5A1, ESRRA, SHBG | CA1 3310/4885CA2 2714/4885CA4 3869/4885 |
| US-20080114048-A1 | NOVEL TETRACYCLIC HETEROATOM CONTAINING DERIVATIVES USEFUL AS SEX STEROID HORMONE RECEPTOR MODULATORS | NR5A1, ESRRA, SHBG | CA1 3310/4885CA2 2714/4885CA4 3869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.